부산대학교 도서관

Interstitial lung disease (ILD) is very common in systemic sclerosis (SSc) and the leading cause of death. High-resolution computed tomography is a sensitive tool for the diagnosis of ILD in SSc and is abnormal in up to 90% of patients. The most common radiographic and histopathologic pattern seen in these patients is one of nonspecific interstitial pneumonia. Despite the high incidence of disease, the prognosis for most patients is good and those who progress tend to do so early in the course of disease. Treatment options are limited by a paucity of placebo-controlled trials. Data for use of cyclophosphamide and mycophenolate mofetil exist and there is an ongoing trial comparing these two treatments. Although there are limited data to guide us on how to care for these patients, this article proposes a management algorithm. There is ongoing research on new biological treatments as well as the use of biomarkers to predict the course of disease and response to treatment and these may shape the future management of SSc-ILD.
Author(s): Joshua J Solomon [sup.1] , Kevin K Brown [sup.[[dagger]]] [sup.2] KEYWORDS : biomarkers; cyclophosphamide; interstitial lung disease; mycophenolate mofetil; nonspecific interstitial pneumonia; scleroderma; systemic sclerosis Medscape: Continuing Medical Education [...]